Skip to main content

Advertisement

SpringerLink
Log in

Prognostic relevance of 18F-FDG PET uptake in patients with locally advanced, extremity soft tissue sarcomas undergoing neoadjuvant isolated limb perfusion with TNF-α and melphalan

  • Original Article
  • Published:
European Journal of Nuclear Medicine and Molecular Imaging Aims and scope Submit manuscript

Abstract

Purpose

The objective of this study was to determine whether 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) can adequately assess the risk of systemic disease progression in patients with primary, localized, high-grade soft tissue sarcomas of the extremities undergoing neoadjuvant isolated limb perfusion (ILP) with tumour necrosis factor and melphalan.

Methods

This was a retrospective analysis of the files of 35 patients who underwent a PET or PET/CT scan prior to and after ILP followed by surgical resection with curative intent between 2006 and 2012. SUVmax1 was defined as the maximum standardized uptake value (SUV) at diagnosis, SUVmax2 as the maximum SUV after ILP and ΔSUVmax as the percentage difference between SUVmax1 and SUVmax2.

Results

The median follow-up was 40 months for all patients. The median SUVmax1 amounted to 7.6, while the median SUVmax2 was 4.7. The median ΔSUVmax was −44 %. Overall survival (OS) probability at 2 and 5 years amounted to 78 and 70 %, respectively, while metastasis-free survival (MFS) probability at 2 and 5 years was 67 and 64 %, respectively. Receiver-operating characteristic (ROC) curve analysis showed that both SUVmax2 and ΔSUVmax could predict systemic disease progression, while SUVmax1 could not adequately identify patients who went on to develop metastatic disease. The optimal cut-off value was 6.9 for SUVmax2 and −31 % for ΔSUVmax. Patients with an SUVmax2 <6.9 had a 2-year MFS of 80 %, compared to 31 % for patients with an SUVmax2 ≥ 6.9 (p < 0.001). Patients with a ΔSUVmax < −31 %, i.e. patients with a higher metabolic response, had an MFS of 76 % at 2 years, compared to 42 % for patients with a ΔSUVmax ≥ −31 % (p = 0.050).

Conclusion

SUVmax after ILP for primary, locally advanced, non-metastatic high-grade soft tissue sarcomas of the extremities appears to be significantly correlated with prognosis. Whether patients with a high SUVmax after ILP will benefit from standard or experimental adjuvant systemic treatment options should be evaluated in future studies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  1. Clarkson P, Ferguson PC. Primary multidisciplinary management of extremity soft tissue sarcomas. Curr Treat Options Oncol 2004;5:451–62.

    Article  PubMed  Google Scholar 

  2. Rosenberg SA, Tepper J, Glatstein E, Costa J, Baker A, Brennan M, et al. The treatment of soft-tissue sarcomas of the extremities: prospective randomized evaluations of (1) limb-sparing surgery plus radiation therapy compared with amputation and (2) the role of adjuvant chemotherapy. Ann Surg 1982;196:305–15.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  3. Andreou D, Fehlberg S, Tiedke C, Niethard M, Tunn PU. Revolutionizing the treatment of locally advanced extremity soft tissue sarcomas: a review on TNFa-based isolated limb perfusion. Eur Surg 2009;41:176–88.

    Article  Google Scholar 

  4. Tunn PU, Kettelhack C, Durr HR. Standardized approach to the treatment of adult soft tissue sarcoma of the extremities. Recent Results Cancer Res 2009;179:211–28.

    Article  PubMed  Google Scholar 

  5. Benz MR, Allen-Auerbach MS, Eilber FC, Chen HJ, Dry S, Phelps ME, et al. Combined assessment of metabolic and volumetric changes for assessment of tumor response in patients with soft-tissue sarcomas. J Nucl Med 2008;49:1579–84. doi:10.2967/jnumed.108.053694.

    Article  PubMed  Google Scholar 

  6. Grabellus F, Stylianou E, Umutlu L, Sheu SY, Lehmann N, Taeger G, et al. Size-based clinical response evaluation is insufficient to assess clinical response of sarcomas treated with isolated limb perfusion with TNF-alpha and melphalan. Ann Surg Oncol 2012;19:3375–85. doi:10.1245/s10434-012-2408-1.

    Article  PubMed  Google Scholar 

  7. Eary JF, Hawkins DS, Rodler ET, Conrad 3rd EU. (18)F-FDG PET in sarcoma treatment response imaging. Am J Nucl Med Mol Imaging 2011;1:47–53.

    PubMed Central  PubMed  Google Scholar 

  8. Schuetze SM, Rubin BP, Vernon C, Hawkins DS, Bruckner JD, Conrad 3rd EU, et al. Use of positron emission tomography in localized extremity soft tissue sarcoma treated with neoadjuvant chemotherapy. Cancer 2005;103:339–48. doi:10.1002/cncr.20769.

    Article  PubMed  Google Scholar 

  9. Benz MR, Evilevitch V, Allen-Auerbach MS, Eilber FC, Phelps ME, Czernin J, et al. Treatment monitoring by 18F-FDG PET/CT in patients with sarcomas: interobserver variability of quantitative parameters in treatment-induced changes in histopathologically responding and nonresponding tumors. J Nucl Med 2008;49:1038–46. doi:10.2967/jnumed.107.050187.

    Article  PubMed  Google Scholar 

  10. Evilevitch V, Weber WA, Tap WD, Allen-Auerbach M, Chow K, Nelson SD, et al. Reduction of glucose metabolic activity is more accurate than change in size at predicting histopathologic response to neoadjuvant therapy in high-grade soft-tissue sarcomas. Clin Cancer Res 2008;14:715–20. doi:10.1158/1078-0432.CCR-07-1762.

    Article  CAS  PubMed  Google Scholar 

  11. Herrmann K, Benz MR, Czernin J, Allen-Auerbach MS, Tap WD, Dry SM, et al. 18F-FDG-PET/CT imaging as an early survival predictor in patients with primary high-grade soft tissue sarcomas undergoing neoadjuvant therapy. Clin Cancer Res 2012;18:2024–31. doi:10.1158/1078-0432.CCR-11-2139.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  12. van Ginkel RJ, Hoekstra HJ, Pruim J, Nieweg OE, Molenaar WM, Paans AM, et al. FDG-PET to evaluate response to hyperthermic isolated limb perfusion for locally advanced soft-tissue sarcoma. J Nucl Med 1996;37:984–90.

    PubMed  Google Scholar 

  13. van Ginkel RJ, Kole AC, Nieweg OE, Molenaar WM, Pruim J, Koops HS, et al. L-[1-11C]-tyrosine PET to evaluate response to hyperthermic isolated limb perfusion for locally advanced soft-tissue sarcoma and skin cancer. J Nucl Med 1999;40:262–7.

    PubMed  Google Scholar 

  14. Been LB, Suurmeijer AJ, Elsinga PH, Jager PL, van Ginkel RJ, Hoekstra HJ. 18F-fluorodeoxythymidine PET for evaluating the response to hyperthermic isolated limb perfusion for locally advanced soft-tissue sarcomas. J Nucl Med 2007;48:367–72.

    CAS  PubMed  Google Scholar 

  15. Gaston LL, Di Bella C, Slavin J, Hicks RJ, Choong PF. 18F-FDG PET response to neoadjuvant chemotherapy for Ewing sarcoma and osteosarcoma are different. Skeletal Radiol 2011;40:1007–15. doi:10.1007/s00256-011-1096-4.

    Article  PubMed  Google Scholar 

  16. Beyer T, Antoch G, Müller S, Egelhof T, Freudenberg LS, Debatin J, et al. Acquisition protocol considerations for combined PET/CT imaging. J Nucl Med 2004;45 Suppl 1:25S–35S.

    PubMed  Google Scholar 

  17. Folpe AL, Lyles RH, Sprouse JT, Conrad 3rd EU, Eary JF. (F-18) fluorodeoxyglucose positron emission tomography as a predictor of pathologic grade and other prognostic variables in bone and soft tissue sarcoma. Clin Cancer Res 2000;6:1279–87.

    CAS  PubMed  Google Scholar 

  18. Eary JF, O’Sullivan F, Powitan Y, Chandhury KR, Vernon C, Bruckner JD, et al. Sarcoma tumor FDG uptake measured by PET and patient outcome: a retrospective analysis. Eur J Nucl Med Mol Imaging 2002;29:1149–54. doi:10.1007/s00259-002-0859-5.

    Article  CAS  PubMed  Google Scholar 

  19. Perkins NJ, Schisterman EF. The inconsistency of “optimal” cutpoints obtained using two criteria based on the receiver operating characteristic curve. Am J Epidemiol 2006;163:670–5. doi:10.1093/aje/kwj063.

    Article  PubMed Central  PubMed  Google Scholar 

  20. Grabellus F, Kraft C, Sheu-Grabellus SY, Bauer S, Podleska LE, Lauenstein TC, et al. Tumor vascularization and histopathologic regression of soft tissue sarcomas treated with isolated limb perfusion with TNF-alpha and melphalan. J Surg Oncol 2011;103:371–9. doi:10.1002/jso.21724.

    Article  CAS  PubMed  Google Scholar 

  21. Kaplan E, Maier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457–81.

    Article  Google Scholar 

  22. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966;50:163–70.

    CAS  PubMed  Google Scholar 

  23. Khanna C, Hunter K. Modeling metastasis in vivo. Carcinogenesis 2005;26:513–23. doi:10.1093/carcin/bgh261.

    Article  CAS  PubMed  Google Scholar 

  24. Demicheli R, Retsky MW, Hrushesky WJ, Baum M, Gukas ID. The effects of surgery on tumor growth: a century of investigations. Ann Oncol 2008;19:1821–8. doi:10.1093/annonc/mdn386.

    Article  CAS  PubMed  Google Scholar 

  25. Huth JF, Mirra JJ, Eilber FR. Assessment of in vivo response to preoperative chemotherapy and radiation therapy as a predictor of survival in patients with soft-tissue sarcoma. Am J Clin Oncol 1985;8:497–503.

    Article  CAS  PubMed  Google Scholar 

  26. Kasper B, Dietrich S, Dimitrakopoulou-Strauss A, Strauss LG, Haberkorn U, Ho AD, et al. Early prediction of therapy outcome in patients with high-risk soft tissue sarcoma using positron emission tomography. Onkologie 2008;31:107–12. doi:10.1159/000113795.

    Article  PubMed  Google Scholar 

  27. Schwarzbach MH, Hinz U, Dimitrakopoulou-Strauss A, Willeke F, Cardona S, Mechtersheimer G, et al. Prognostic significance of preoperative [18-F] fluorodeoxyglucose (FDG) positron emission tomography (PET) imaging in patients with resectable soft tissue sarcomas. Ann Surg 2005;241:286–94.

    Article  PubMed Central  PubMed  Google Scholar 

  28. Eggermont AM, de Wilt JH, ten Hagen TL. Current uses of isolated limb perfusion in the clinic and a model system for new strategies. Lancet Oncol 2003;4:429–37.

    Article  PubMed  Google Scholar 

  29. Italiano A, Delva F, Mathoulin-Pelissier S, Le Cesne A, Bonvalot S, Terrier P, et al. Effect of adjuvant chemotherapy on survival in FNCLCC grade 3 soft tissue sarcomas: a multivariate analysis of the French Sarcoma Group Database. Ann Oncol 2010;21:2436–41. doi:10.1093/annonc/mdq238.

    Article  CAS  PubMed  Google Scholar 

  30. ESMO/European Sarcoma Network Working Group. Soft tissue and visceral sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012;23 Suppl 7:vii92–9. doi:10.1093/annonc/mds253.

    Google Scholar 

  31. Woll PJ, Reichardt P, Le Cesne A, Bonvalot S, Azzarelli A, Hoekstra HJ, et al. Adjuvant chemotherapy with doxorubicin, ifosfamide, and lenograstim for resected soft-tissue sarcoma (EORTC 62931): a multicentre randomised controlled trial. Lancet Oncol 2012;13:1045–54. doi:10.1016/S1470-2045(12)70346-7.

    Article  CAS  PubMed  Google Scholar 

Download references

Conflicts of interest

None.

Author information

Authors and Affiliations

  1. Department of General Orthopedics and Tumor Orthopedics, Münster University Hospital, Albert-Schweitzer-Campus 1, 48149, Münster, Germany

    Dimosthenis Andreou

  2. Department of Orthopedic Oncology, Sarcoma Center Berlin-Brandenburg, HELIOS Klinikum Berlin-Buch, Schwanebecker Chaussee 50, 13125, Berlin, Germany

    Dimosthenis Andreou & Per-Ulf Tunn

  3. Department of Nuclear Medicine, HELIOS Klinikum Berlin-Buch, Schwanebecker Chaussee 50, 13125, Berlin, Germany

    Henrike Boldt

  4. Department of Hematology, Oncology and Palliative Care, Sarcoma Center Berlin-Brandenburg, HELIOS Klinikum Bad Saarow, Pieskower Straße 33, 15526, Bad Saarow, Germany

    Daniel Pink

  5. Department of Radiology, HELIOS Klinikum Berlin-Buch, Schwanebecker Chaussee 50, 13125, Berlin, Germany

    Björn Jobke

  6. Department of Pathology, Sarcoma Center Berlin-Brandenburg, HELIOS Klinikum Emil von Behring, Walterhöferstraße 11, 14165, Berlin, Germany

    Mathias Werner

  7. Department of Internal Medicine I, University Hospital Carl Gustav Carus Dresden, Fetscherstraße 74, 01307, Dresden, Germany

    Markus Schuler

  8. Department of Interdisciplinary Oncology, Sarcoma Center Berlin-Brandenburg, HELIOS Klinikum Berlin-Buch, Schwanebecker Chaussee 50, 13125, Berlin, Germany

    Peter Reichardt

Authors
  1. Dimosthenis Andreou
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Henrike Boldt
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Daniel Pink
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Björn Jobke
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Mathias Werner
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Markus Schuler
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Peter Reichardt
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Per-Ulf Tunn
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Dimosthenis Andreou.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Andreou, D., Boldt, H., Pink, D. et al. Prognostic relevance of 18F-FDG PET uptake in patients with locally advanced, extremity soft tissue sarcomas undergoing neoadjuvant isolated limb perfusion with TNF-α and melphalan. Eur J Nucl Med Mol Imaging 41, 1076–1083 (2014). https://doi.org/10.1007/s00259-013-2680-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00259-013-2680-8

Keywords

Search

Navigation